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Abstract Many dementia patients exhibit behavioral and
psychological symptoms (BPSD), including psychosis
and depression. Although antipsychotics are frequently pre-
scribed off-label, they can have marked side effects. In addi-
tion, comparative preclinical studies of their effects are sur-
prisingly scarce, and strategies for discovery of novel
pharmacotherapeutics are lacking. We therefore compared
eight antipsychotics in rat behavioral tests of psychosis,
antidepressant-like activity, and cognitive impairment as a
basis for preclinical evaluation of new drug candidates. The
methods used in this study include inhibition of MK-801-
induced hyperactivity, forced swim test (FST), passive avoid-
ance (PA), spontaneous locomotor activity, and catalepsy. The
drugs exhibited antipsychotic-like activity in the MK-801 test
but with diverse profiles in the other models. Risperidone
impaired PA performance, but with some dose separation
versus its actions in the MK-801 test. In contrast, clozapine,
olanzapine, lurasidone, and asenapine showed little or no dose
separation in these tests. Aripiprazole did not impair PA
performance but was poorly active in the MK-801 test. Di-
verse effects were also observed in the FST: chlorpromazine
was inactive and most other drugs reduced immobility over
narrow dose ranges, whereas clozapine reduced immobility
over a wider dose range, overlapping with antipsychotic ac-
tivity. Although the propensity of second-generation antipsy-
chotics to produce catalepsy was lower, they all elicited pro-
nounced sedation. Consistent with clinical data, most current-
ly available second-generation antipsychotics induced cogni-
tive and motor side effects with little separation from
therapeutic-like doses. This study provides a uniform in vivo
comparative basis onwhich to evaluate future early-stage drug
candidates intended for potential pharmacotherapy of BPSD.
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Introduction
Dementia is a syndrome of progressive deterioration of cogni-
tive abilities associated with psychiatric and behavioral distur-
bances and difficulties in carrying out daily functions (Hersch
and Falzgraf 2007). In view of increased life expectancy and
population aging, dementia represents a growing medical prob-
lem. Indeed, the global prevalence of dementia is estimated to be
3.9 % in individuals over the age of 60 years (Ferri et al. 2005),
and a large majority of these (as many as 60 % of community-
dwelling dementia patients) also experience behavioral and
psychological symptoms of dementia (BPSD) at some time.
The most troublesome symptoms include psychosis (delusions
and hallucinations), depression, dis-inhibition, irritability, verbal
and physical aggression, agitation, and anxiety (Jeste et al.
2008). Between 40 and 60 % of patients suffering from demen-
tia experience depressive symptoms at some stage of the disease
(Hersch and Falzgraf 2007), and the prevalence of psychotic
symptoms can reach 63 % for delusions and up to 41 % for
hallucinations in certain patient populations (Jeste et al. 2008).
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Until the mid-1990s, first-generation antipsychotics were
the drugs of choice for BPSD treatment, especially when
delusions and hallucinations were present. Indeed, although
haloperidol has no effect on agitation or behavioral symptoms
as a whole, it reduces aggression. Other meta-analyses indi-
cated no major difference between first-generation antipsy-
chotics in efficacy for BPSD (Sink et al. 2005).
Subsequently, second-generation ‘atypical’ antipsychotics
partially replaced first-generation antipsychotics in the treatment
of BPSD (DeDeyn et al. 2005). A Cochrane review (Ballard and
Waite 2006) of 16 clinical trials with atypical antipsychotics in
the treatment of BPSD revealed that risperidone and olanzapine
were effective in the treatment of aggression, and risperidonewas
superior to placebo in the treatment of dementia-related psycho-
sis. However, both drugs elicited significantly increased adverse
cardiovascular events and extrapyramidal symptoms (EPS). In
comparison, aripiprazole showed no benefits over placebo in
controlling delusions and hallucinations in patients with
Alzheimer’s disease and psychosis (De Deyn et al. 2005). The
use of antipsychotics in BPSD is further complicated by the fact
that these drugs often exacerbate preexisting cognitive deficits
and produce EPS (Fasano et al. 2012; Jeste et al. 2008), empha-
sizing the view that currently marketed antipsychotics may not
constitute acceptable therapies for elderly patients with BPSD
(Gareri et al. 2014). In fact, since 2005, the US Food and Drug
Administration (FDA) has required the inclusion of alerts on the
package inserts of atypical antipsychotics drugs. Such “boxed
warnings” are related to the risk of serious adverse effects that
can be induced by atypical antipsychotics being prescribed
among elderly patients with dementia. Nevertheless, antipsy-
chotics continue to be widely prescribed for BPSD (Schneider
et al. 2006b; Schulze et al. 2013b), no doubt largely due to the
absence of improved drugs with safer and more effective thera-
peutic profiles (Schulze et al. 2013a).
Me e t i n g t h e med i c a l n e e d f o r e f f i c a c i o u s
pharmacotherapeutics to treat BPSD would require the devel-
opment of drug discovery strategies for evaluation of novel
compounds in experimental tests relevant to the disorder. Spe-
cifically, novel drugs should alleviate psychotic and/or
depressive-like symptoms and not interfere with cognitive or
motor performance (Fasano et al. 2012; Jeste et al. 2008).
However, drug discovery efforts in this area are in their infancy,
and no recognized animal models of BPSD are currently avail-
able, complicating early first-in-vivo drug screening. Hence,
pharmacological profiling of novel drug candidates must cur-
rently rely on a battery of known tests that address different
symptoms. Such a strategy is described in a recent publication
characterizing the profile of ADN-1184, a novel compound
with potential anti-BPSD activity (Kołaczkowski et al. 2013).
The compound was active in models of antipsychotic-like
activity without eliciting catalepsy or impairment of passive
avoidance (PA) performance. In the rat forced swim test (FST),
ADN-1184 decreased immobility time, suggesting that it
possesses some antidepressant-like activity. However, results
on ADN-1184 need to be compared with those on existing
antipsychotics characterized under uniform conditions in order
to determine if the compound has distinguishing features that
suggest potential therapeutic superiority. However, relevant
comparative pre-clinical pharmacological data are surprisingly
scarce and fragmentary, and parallel studies concerning the
effects of antipsychotics in rodent models of psychosis, depres-
sion, and memory are largely absent. In addition, novel drugs
such as asenapine and lurasidone (Ishibashi et al. 2010;
Marston et al. 2009) have recently become available and remain
to be fully characterized. Lurasidone is reputed to display
favorable activity in models of cognitive activity (Yuen et al.
2012), but replication studies from other laboratories are mostly
lacking. There is therefore a need to characterize established
antipsychotics using the same animal models that were used to
characterize ADN-1184 and that are commonly used as first-
line screening procedures for novel psychotropic agents.
Here, we characterized the antipsychotic-like activity of
eight antipsychotics using inhibition of hyperlocomotion in-
duced by the non-competitive N-methyl-D-aspartate (NMDA)
receptor antagonist, dizocilpine (MK-801) (Andiné et al.
1999). Effects of drugs on spontaneous activity and catalepsy
induction were recorded in order to assess their potential to
induce motor deficits and EPS. We used reduction of immo-
bility in the FST as a measure of antidepressant efficacy and
disruption of performance in the PA test as a measure of the
drugs’ potential for impairing cognitive processes (Ishiyama
et al. 2007; Porsolt et al. 1978; Schatzberg and Nemeroff
2009). Imipramine was used as comparator for the FST, and
scopolamine was used as comparator in PA experiments.
Two first-generation antipsychotics (haloperidol, chlor-
promazine) were compared with well-established second-
generation atypical antipsychotics (clozapine, olanzapine, ris-
peridone, aripiprazole) and with lurasidone and asenapine,
which have been recently introduced to the market
(Ishibashi et al. 2010; Schatzberg and Nemeroff 2009). As
stated above, a lack of clear-cut separation between doses
producing antidepressant and antipsychotic effects and doses
leading to deterioration of cognitive and motor functions can
limit the use of antipsychotic drugs for BPSD (Ballard et al.
2009; Jeste et al. 2008; Potenza and McDougle 1998). There-
fore, a key aim of the present study was to asses the relation-
ship between antipsychotic, antidepressant, motor impairing,
and amnestic doses of a wide range of antipsychotic drugs.
Methods
Subjects
Drug-naive male Wistar rats (Charles River, Sulzfeld, Germa-
ny) weighing 200–225 g on arrival were used (n=7–8 rats per
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group). Animals were supplied by the breeder 2–3 weeks
before the onset of behavioral procedures. Rats were housed
four per standard plastic cage and kept in a roomwith constant
environmental conditions (22±1 °C, relative humidity 60%, a
12:12 light–dark cycle with lights on at 7:00 a.m.). During this
time, the subjects were weighted and handled several times.
Tap water and standard lab chow (Labofeed H, WPIK,
Kcynia, Poland) were available ad libitum. All tests were
carried out in a sound-attenuated experimental room between
09:00 a.m. and 3:00 p.m. Treatment of rats in the present study
was in full accordance with the ethical standards laid down in
respective Polish and European (Directive no. 86/609/EEC)
regulations. All procedures were reviewed and approved by a
local ethics committee.
MK-801-induced hyperlocomotion
The tests used in the present study were recently described by
Kołaczkowski et al. (2013). Antipsychotic-like activity was
assessed by inhibition of the hyperactivity elicited by the
NMDA receptor antagonist, MK-801 (Andiné et al. 1999).
Briefly, groups of drug-naive rats (n=7–8) were transferred in
their home cages to the experimental room 24 h prior to testing
and allowed to habituate for 60 min and returned to colony
room. The next day, locomotor activity was assessed in black
octagonal open fields (80 cm in diameter, 30 cm high) under
dim light and continuous white noise (65 dB). Each animal
was placed in the central part of the open field and allowed to
freely explore the whole area for 30min. Subjects did not have
visual contact with other rats during the experiment. Forward
locomotion (cm/30 min) was registered and analyzed with the
aid of the computerized video tracking system (Videomot,
TSE, Bad Homburg, Germany).
Rats were pre-administered i.p. or s.c. with antipsychotic
drug or its vehicle 60 min before the start of the locomotor
activity test. Fifteen minutes before the start of the test, rats
were administered MK-801 (0.3 mg/kg i.p.). To assess spon-
taneous locomotor activity, rats were administered saline
15 min prior the test.
Forced swimming test
The procedure used in the study to determine antidepressant-
like activity was a modification of the technique described by
Porsolt et al. (1978). Briefly, rats were individually placed in
glass cylinders (40 cm in height, 17 cm in diameter) filled with
water (temperature 23±1 °C) at a height that made it impos-
sible to reach the bottom with hind paws (25 cm). There were
two swimming sessions separated by 24 h: an initial 15-min
pre-test and a 5-min test. The duration of immobility (s) in the
test session was recorded by a blinded observer located in an
adjacent room with the aid of a video camera. A rat was
considered immobile when it floated not moving except to
keep the head above the water surface. Animals were injected
with vehicle or drugs 60 min. i.p. or s.c. before the test.
Step-through passive avoidance test
Effects of antipsychotics on memory function were evaluated
using a step-through passive avoidance test (Ishiyama et al.
2007). Briefly, the passive avoidance apparatus (PACS-30,
Columbus Instruments, Columbus, OH, USA) comprised four
identical stainless-steel cages with black Plexiglas covers.
Each cage consisted of a lighted and a dark compartment
(23×23×23 cm) and a stainless-steel grid floor. The two
compartments were separated by an automated sliding door.
In the training (acquisition) session, the animals were individ-
ually placed in the lighted compartment and allowed to ex-
plore it freely for 10 s. The sliding door was then opened, and
the step-through latency for animals to enter the dark com-
partment was measured with a 300-s cutoff time. As soon as
the animals entered the dark compartment, the door was
closed. An inescapable foot-shock (0.5 mA pulse monopolar
current for 3 s) was delivered 3 s later through the grid floor
with a monopolar current shock generator (EACS-30,
Columbus Instruments). The tested compound, or its vehicle,
was administered 60 min before the start of the training
session. All control vehicle-treated animals entered the dark
compartment during the training session and received a foot-
shock. Drug-treated animals that did not enter the dark com-
partment in the training session were not subjected to the test
session. In the present study, all the tested animals entered the
dark side, except those that had been treated with haloperidol
at doses of 0.3 and 1.0 mg/kg. At these doses, 50 % of the rats
entered the dark compartment.
The test session was performed 24 h after the training
session using the same paradigm but without the foot-shock
and drug/vehicle injections (Ishiyama et al. 2007). Step-
through latencies for animals to enter the dark compartment
were measured with a 300-s cutoff time. Drug-induced de-
creases in step-through latencies to enter the dark compart-
ment in the test session were treated as a measure of drug’s
“amnestic” effects.
Catalepsy
Cataleptogenic responses were assessed using the bar test.
Each rat was placed on a clean, smooth table with the wooden
bar (2×3×25 cm, H×W×L) suspended 10 cm above the
working surface. The animal’s hindlimbs were freely placed
on the table, the tail laid out to the back, and the forelimbs
gently placed over the bar. The length of time the animal
touched the bar with both front paws was measured up to a
cutoff time of 180 s. Results of each trial were scored as
follows: 0 for holding the position for <15 s, 1 for holding it
for 15–29.9 s, 2 for holding it for 30–59.9 s, and a maximum
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score of 3 for staying on the bar for >60 s (Ogren et al. 1986).
The minimum cataleptogenic dose was defined as the lowest
dose inducing a mean catalepsy score of ≥1. Catalepsy was
scored 30, 60, and 120 min after administration of vehicle or a
test drug.
Data analysis
Data were analyzed by one-way analysis of variance
(ANOVA). The Newman–Keuls test was used for post hoc
comparisons. Induction of hyperlocomotion by MK-801
(MK-801 vs. saline) was confirmed by Student’s t test. The
reversal of MK-801-induced hyperactivity by antipsychotic
drugs was analyzed by ANOVA. In the case of the passive
avoidance test, data were not normally distributed so step-
through latencies were analyzed with the aid of the Kruskal–
Wallis and Mann–Whitney non-parametric tests. p values
≤0.05 were considered significant. The Statistica 8.0 software
package forWindows (StatSoft, Tulsa, OK, USA) was used to
analyze all data. The lowest drug dose eliciting a significant
effect was defined as a minimal effective dose (MED).
Drugs
MK-801 (Sigma-Aldrich, Poznan, Poland) was dissolved in
sterile physiological saline (0.9 % NaCl; Baxter, Warsaw,
Poland) and administered i.p. in a volume of 1.0 ml/kg.
Antipsychotic drugs were also administered i.p. (except halo-
peridol s.c.) in injection volumes that were adjusted to the
minimum necessary to ensure full solution of the compounds
in the vehicle. Unless stated, all drugs were synthesized by
Adamed Ltd. Aripiprazole, olanzapine, risperidone,
lurasidone, and asenapine were suspended in a 1.5 % aqueous
solution of Tween 80 (Sigma-Aldrich) and administered in a
volume of 1 ml/kg (olanzapine, risperidone) or 2 ml/kg
(aripiprazole, lurasidone, asenapine). Clozapine, was
suspended in a 3 % aqueous solution of Tween 80 with a
few drops of glacial acetic acid and administered i.p. in a
volume of 3 ml/kg. Chlorpromazine (ampoules 25 mg/ml;
Fenactil, WZF Polfa S.A., Warsaw, Poland) was diluted with
physiological saline and administered i.p. in a volume of
1.2 ml/kg. Haloperidol (ampoules 5 mg/ml; Haloperidol
WZF, WZF Polfa S.A.) was diluted with physiological saline
and administered in a volume of 1 ml/kg. Imipramine hydro-
chloride and (−)-scopolamine hydrobromide trihydrate
(Sigma-Aldrich) were dissolved in physiological saline and
administered i.p. in a volume of 2.0 ml/kg (control animals
received vehicle in the same volume as drug-treated animals).
All doses refer to the quantity of free base except for chlor-
promazine and lurasidone (hydrochloride salts, as clinically
used).
Results
Antipsychotic-like activity: MK-801-induced
hyperlocomotion
As expected (Schatzberg and Nemeroff 2009), MK-801
dose-dependently increased forward locomotion activity in
all the tested groups. MK-801-treated animals showed a
significant increase in distance travelled (Student’s t test,
all T’s>2.6, p’s<0.05). All drugs, except aripiprazole,
dose-dependently and significantly (all F’s>3.6, all p’s<
0.05) antagonized hyperlocomotion induced by MK-801
(Fig. 1; Table 2). Haloperidol, risperidone, and asenapine
were the most potent in antagonizing MK-801-induced
hyperlocomotion, and chlorpromazine was the least potent
(Table 1). Aripiprazole did not significantly diminish MK-
801-induced hyperlocomotion even at a high dose
(100 mg/kg i.p.) [F(4, 35)=0.51, p>0.05].
Antidepressant-like activity: forced swimming test
Duration of immobility in vehicle-treated subjects was
258–292 s. The tricyclic antidepressant, imipramine,
dose-dependently reduced immobility in the FST, consis-
tent with antidepressant-like properties (Porsolt et al.
1978). Maximal reduction of immobility by imipramine
at 10 mg/kg was 25 % of control values (Table 2;
Fig. 2) (F(2, 21)=5.1, p<0.05, the post hoc Newman–
Keuls test revealed significant effect at dose 10 mg/kg,
p<0.01). Among the antipsychotic drugs, chlorpromazine
did not reduce the duration of immobility in this test (F(3,
28)=1.8, p>0.05). All other compounds modestly, but
significantly, reduced immobility time at least at one dose
(all F’s>3.2, p’s<0.05). Notably, most of the tested anti-
psychotics evoked reduction in immobility time with U-
shaped dose–response curves, as shown in Fig. 2. In
contrast, clozapine evoked significant antidepressant-like
effects at the two highest doses tested, 10 and 30 mg/kg.
Memory impairment: passive avoidance test
The muscarinic receptor antagonist, scopolamine, dose-
dependently abolished passive avoidance response, consistent
with memory impairment in this procedure (H(3)=16.5,
p<0.01, Mann–Whitney U test revealed significant effects at
doses 0.3 and 1.0 mg/kg, p<0.05, and at dose 3.0 mg/kg,
p<0.01). Some antipsychotics (chlorpromazine, haloperidol,
risperidone, aripiprazole, and asenapine) produced dose-
dependent prolongation in step-through latency during the
training (acquisition) session, suggesting motor interference
consecutive to sedation or catalepsy.
In the test (expression) sessions, all drugs, except
aripiprazole, significantly (Kruskal–Wallis ANOVA: all
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H’s>10.0, all p’s<0.05) reduced the step-through latency
(Fig. 3). Aripiprazole at 10–100 mg/kg did not modify the
passive avoidance response (Kruskal–Wallis ANOVA H(3)=
3.0, p>0.05). As shown in Table 1, haloperidol, risperidone,
and asenapine were the most potent in reducing step-through
latency.
Fig. 1 Effects of antipsychotics on hyperlocomotion induced by MK-
801. Each symbol represents mean±SEM distance traveled (n=7–8) in
the 16–45-min period after MK-801 administration. Test compound or
vehicle was administered 45 min before MK-801 (0.3 mg/kg). *p<0.05,
**p<0.01, compared with MK-801-injected control group using New-
man–Keuls post hoc test, following significant ANOVA. The lower
dotted lines represent the average locomotor activity of vehicle/saline
groups
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Movement impairment: inhibition of spontaneous locomotion
and catalepsy
As expected, all antipsychotics inhibited spontaneous loco-
motion. In most cases, the MEDs were broadly similar to
those that reduced MK-801-induced hyperactivity (Table 1).
However, chlorpromazine and aripiprazole inhibited sponta-
neous locomotion at doses at least 10-fold lower than those
active in the MK-801 test.
Most of the antipsychotics also elicited catalepsy, whereas
vehicle-treated animals did not exhibit any (data not shown).
The MED values were, in most cases, similar or slightly
higher than those active in the MK-801 test. In contrast,
clozapine, aripiprazole, and lurasidone did not elicit catalepsy
even at the highest dose tested (100mg/kg; Table 1). This dose
of clozapine did, however, elicit seizures in some animals.
Discussion
The principal finding of the present study is that currently-
marketed second-generation antipsychotics offer limited sep-
aration between doses active in rat models of antipsychotic-
like activity and memory impairment. Although, in accor-
dance with clinical data, their propensity to produce catalepsy
was lower, the drugs all elicited pronounced sedation. Indeed,
although antipsychotics are commonly used to treat BPSD
off-label, little information is available that directly compares
antipsychotics in standardized pharmacological tests that may
be relevant to this disorder. Thus, whereas previous studies
have reported data on antipsychotic-like properties (e.g., inhi-
bition of MK-801-induced hyperlocomotion), comparisons of
these activities with those observed in PA and FST have not
been thoroughly characterized. Such early-stage comparative
information is important to provide a basis on which to select
future drug candidates at a preclinical level. Indeed, although
BPSD is a serious and unmet medical need, there is currently
no consensus for identifying novel drugs with improved ther-
apeutic potential. The present study therefore provides a com-
parative dataset for novel drug candidates such as the recently
reported compound, ADN-1184 (Kołaczkowski et al. 2013).
Activity of compounds in tests of antipsychotic-like efficacy
and motor control
Inhibition of MK-801-induced hyperactivity was used here as
a measure of antipsychotic-like activity. This test was chosen
because NMDA receptors are involved in various forms of
dementia (Olivares et al. 2012) and NMDA receptor density is
decreased in the frontal cortex of postmortem brain samples of
Alzheimer’s disease patients (Scheuer et al. 1996). This sug-
gests that dysfunction of NMDA receptors may underlie some
aspects of the disease, such as susceptibility to psychotic
symptoms. In the present experiments, most of the antipsy-
chotics abolished MK-801-induced hyperactivity, as expect-
ed. Among the recent drugs, lurasidone and asenapine, but not
aripiprazole, displayed robust activity in this test. In contrast,
other authors have reported significant inhibition by
aripiprazole of MK-801 and ketamine-induced hyperactivity
in rat and mouse (Leite et al. 2008; Nordquist et al. 2008). One
Table 1 Action of antipsychotic drugs on five behavioral tests in rat
MK-801
hyperlocomotion
Spont. loco. Catalepsy Forced swim test Passive
avoidance
MED
ratio
PA/MKMED MED MED FST:
active doses
Immobility: % of vehicle
(% of imipramine)
MED
Chlorpromazine 30.0 (3–30) 3.0 (1–10) 30 (3–30) Not active (1–10) Not active 30.0 (3–30) 1
Haloperidol 0.1 (0.01–0.1) 0.03 (0.01–0.1) 0.1 (0.03–0.3) 0.003, 0.01 (0.003–0.1) −7±2 (28) 0.3 (0.1–1) 3
Clozapine 3.0 (1–10) 10 (1–10) >100a (10–100) 10.0, 30.0 (0.3–30) −11±5 (44) 10 (1.0–10) 3
Olanzapine 3.0 (0.3–3) 1 (0.3–3) 10 (1–10) 1.0 (0.3–3) −11±4 (44) 3.0 (1–10) 1
Risperidone 0.3 (0.1–3) 1 (0.3–3) 10 (0.3–10) 0.3 (0.1–3) −12±6 (48) 3 (0.3–3) 10
Aripiprazole >100 (3–100) 10 (3–100) >100 (10–100) 3.0 (1–30) −14±5 (56) >100 (10–100) n.d.
Lurasidone 3.0 (1–10) 3.0 (1–10) >100 (10–100) 1.0 (0.3–3) −14±3 (56) 10.0 (1–10) 3
Asenapine 0.3 (0.1–1) 1.0 (0.1–1) 3 (1–10) 0.1 (0.03–0.3) −12±4 (48) 0.3 (0.1–1) 1
Imipramine – – – 10 (3–10) −25±8 (100) – –
Scopolamine – – – – – 0.3 (03–3) –
Numbers are minimal effective doses (MED) in milligrams per kilogram. Unless otherwise indicated, numbers in brackets refer to the dose range tested
expressed as milligrams per kilogram. TheMED ratio column shows that for most drugs, there is little separation between doses that elicit antipsychotic-
like activity in the MK-801 test and doses that impair memory performance in the passive avoidance (PA) test. Imipramine ad scopolamine are shown as
comparators for the FST and PA tests, respectively
Spont. Loco spontaneous locomotion, n.d. not determined
a Seizures were noted in some rats
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reason for the discrepancy may be the somewhat variable
response observed with aripiprazole herein (Fig. 1). However,
the D2 receptor partial agonist properties of aripiprazole likely
also render it less adapted to antagonizing hyperlocomotion
elicited by NMDA receptor antagonists, as suggested by
previous studies (Bardin et al. 2007; Leite et al. 2008). Indeed,
the present data correlate with the modest efficacy of
aripiprazole in controlling psychotic symptoms in
Alzheimer’s disease patients (De Deyn et al. 2005;
Schneider et al. 2006a), suggesting that reversal of NMDA
receptor antagonist-induced hyperactivity is an important se-
lection criterion for future drugs aimed at treatment of BPSD.
Overall, the results from the MK-801 test are consistent with
antipsychotic-like activity of the drugs and are important in
the present study because they identify active doses that
constitute measures of central activity for comparison with
the other tests relevant to BPSD (see below).
In tests of catalepsy and inhibition of locomotor activity,
the drugs displayed expected profiles: Most of the drugs
elicited dose-dependent catalepsy, a model of EPS, but cloza-
pine, aripiprazole, and lurasidone did not (Table 1). However,
all the drugs tested herein inhibited spontaneous locomotor
activity, probably reflecting sedative properties, at doses sim-
ilar to those active in the MK-801 test (although
antipsychotic-induced sedation can progressively attenuate
with repeated administration). This is an issue that may be
significant in the context of BPSD drug discovery because
elderly patients may suffer from poor motor coordination and/
or movement disorders (Fasano et al. 2012). Care is necessary
when using drugs that are known to induce motor disruption,
and it would therefore be desirable to identify new drug
candidates that did not suffer from such motor disruption
liability.
Activity of compounds in a test of antidepressant-like efficacy
Mood deficits and depressive symptoms are very common in
patients suffering from dementia (Hersch and Falzgraf 2007),
and the present study shows that antipsychotics used in the
treatment of BPSD have distinct effects in the FST, a classic
model of antidepressant-like activity (Fig. 2). Firstly, the
capacity of antipsychotic drugs to alleviate symptoms of de-
pression is being increasingly recognized with the clinical use
of olanzapine, risperidone, and aripiprazole to treat treatment-
resistant and bipolar depression in conjunction with
established antidepressants (Komossa et al. 2010) or, in the
case of quetiapine, as monotherapy (Weisler et al. 2012).
Clearly, inhibition of monoamine reuptake by SSRIs, SNRIs,
or tricyclic drugs does not provide optimal antidepressant
therapy in many patients. Indeed, established antidepressants
induce a broad increase in monoamine transmission that af-
fects all serotonergic and noradrenergic receptors, including
those that limit antidepressant response, such as, for example,
5-HT6 and 5-HT7. Thus, the efficacy of adjunct treatment
Table 2 Statistical summary of behavioral effects of drugs
Drug MK-801 effect
of MK-801 vs.
saline
MK-801: effect
of antipsychotics vs.
vehicle
Spontaneous
locomotor activity
Forced
swim test
Step-through
latency training
session
Step-through
latency test
session
Chloropromazine t(14)=3.2, p<0.01 F(3, 28)=5.9, p<0.01 F(3, 28)=12.66,
p<0.01
F(3, 28)=1.8,
p>0.05
H(3)=8.96, p<0.05 H(3)=12.6,
p<0.01
Haloperidol t(14)=2.6, p<0.05 F(3, 28)=13.7, p<0.01 F(3, 28)=31.80,
p<0.01
F(4, 35)=7.2,
p<0.01
H(3)=18.2, p<0.01 H(3)=17.7,
p<0.01
Clozapine t(14)=4.0, p<0.01 F(3, 28)=13.8, p<0.01 F(3, 28)=5.50,
p<0.01
F(5, 42)=4.2,
p<0.01
H(3)=1.3, p>0.05 H(3)=10.7,
p<0.05
Olanzapine t(14)=4.2, p<0.01 F(3, 28)=3.6, p<0.05 F(3, 28)=6.10,
p<0.01
F(3, 28)=5.2,
p<0.01
H(3)=5.7, p>0.05 H(3)=7.1,
p>0.05
Risperidone t(14)=6.3, p<0.01 F(4, 35)=5.1, p<0.01 F(3, 26)=7.50,
p<0.01
F(4, 35)=3.1,
p<0.05
H(3)=11.5, p<0.05 H(3)=11.2,
p<0.05
Aripiprazole t(14)=4.8, p<0.01 F(4, 35)=0.5, p>0.05 F(4, 39)=12.10,
p<0.01
F(4, 34)=2.9,
p<0.05
H(3)=9.6, p<0.05 H(3)=3.0,
p>0.05
Lurasidone t(14)=3.2, p<0.01 F(3, 28)=7.7, p<0.01 F(3, 28)=10.8,
p<0.01
F(3, 28)=6.5,
p<0.01
(3)=3.0, p>0.05 H(3)=10.0,
p<0.05
Asenapine t(14)=4.6, p<0.01 F(3, 28)=5.6, p<0.01 F(3, 28)=8.1,
p<0.01
F(3, 28)=6.5,
p<0.01
H(3)=9.3, p<0.05 H(3)=13.3,
p<0.05
Imipramine n.t. n.t. n.t. F(2, 21)=5.1,
p<0.05
n.t. n.t.
Scopolamine n.t. n.t. n.t. n.t. H(3)=2.7, p>0.05 H(3)=16.5,
p<0.01
n.t. not tested
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Fig. 2 Effects of imipramine and antipsychotics on forced swimming
test. Each symbol represents mean±SEM immobility time during 5-min
forced swimming session (n=7–8). Imipramine was administered 30 min
before the test, whereas the other compounds were administered 1 h
before the test. *p<0.05, **p<0.01, compared with vehicle-injected
control group using Newman–Keuls post hoc test, following significant
ANOVA
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with antipsychotics may be due to antagonism of targets that
limit antidepressant action (Carr et al. 2011).
Secondly, in most cases, the effects of the drugs herein were
observed at only a single dose. This is likely a reflection of the
multireceptor profiles of antipsychotics that can, presumably,
interfere with the drugs’ capacity to alleviate mood deficits
over a broad dose range. Olanzapine and lurasidone were
active at doses that are 3-fold lower than those active in the
MK-801 test (Table 1). In contrast, risperidone was active in
the FST at the same dose that was first active in the MK-801
test. Interestingly, very low doses of haloperidol (10–30-fold
lower than antipsychotic-like doses) modestly reduced immo-
bility, probably by antagonism of pre-synaptic D2 receptors
and facilitation of dopaminergic neurotransmission in limbic
regions (Lucas and Spampinato 2000).
Thirdly, the only drug that showed significant activity at
more than one dose, overlapping with antipsychotic activity,
was clozapine. This antipsychotic is among the most effective
in reducing suicidality, a parameter which is strongly connect-
ed to depressed mood (Meltzer 2012). Previous studies of
clozapine in the FST have shown that it is also active under
other experimental conditions (Chindo et al. 2012) and, in a
comparative study in mice, was the only antipsychotic that
showed activity in the tail-suspension test (Wesolowska et al.
2011). It therefore seems that clozapine’s mood-modulating
effects are clearly measurable in pharmacological models, and
this might provide a criterion bywhich to evaluate novel drugs
at an early stage of drug discovery.
Fourthly, the antipsychotics reduced immobility times by
about 10–15 % compared with vehicle-treated subjects. In
comparison, the tricyclic antidepressant imipramine decreased
immobility times by about 25 % at the dose tested. Imipra-
mine’s effect is therefore only about 2-fold greater than that
elicited by antipsychotic drugs, suggesting that the latter’s
effects on mood modulation may be pharmacologically rele-
vant. Nevertheless, higher doses of imipramine are sometimes
reported to elicit larger responses so the antidepressant-like
effects observed with the antipsychotics should be interpreted
with caution (Kitamura et al. 2008). However, it would be
interesting to evaluate the activity of clozapine and other
antipsychotics in the FST upon chronic treatment—their effi-
cacy may increase with repeated administration, as is the case
for reuptake inhibitors, including imipramine (Koek et al.
1998). In addition, in view of the fact that antipsychotics are
often prescribed as adjunct treatment, it would be interesting
to test them in combination with clinically used
antidepressants.
Activity of compounds in a test of cognition/memory
Cognitive disturbance is a major characteristic of dementia
(Hersch and Falzgraf 2007). Hence, it would be desirable to
avoid treating patients suffering from BPSD with drugs that
elicit or accentuate cognitive impairment. Herein, we used a
classic memory test to compare the activity of the antipsy-
chotics. The PA is based on the acquisition, storage, and
retention of aversive Pavlovian conditioning involving short-
and long-term memory processes. In addition, PA also de-
pends on attention, perception (of painful stimuli and visual
discrimination between the compartments), and sensorimotor
integration that involves multiple neurotransmitter systems
(Myhrer 2003). Therefore, PA acquisition is a composite
read-out, and gaining information at an early stage on whether
a compound impairs PA is of value in selection of new drug
candidates for BPSD.
Firstly, the antipsychotics generally showed impairment of
the PA response (Fig. 3; Table 1) although their pattern varied
from one drug to another. Thus, risperidone impaired PA
performance but did so at doses that were 10-fold greater than
those active in the MK-801 test. This suggests that it can
achieve antipsychotic-like activity in the absence of memory
impairment, although its induction of catalepsy and spontane-
ous locomotor activity remain sub-optimal. Other antipsy-
chotics, including clozapine, olanzapine, lurasidone, and
asenapine, showed little (3-fold) or no MED separation be-
tween the PA and MK-801 tests. Accordingly, it would be
desirable to identify drug candidates that did not disrupt
memory performance in early screening tests. Such drugs
could then be further characterized in diverse models of cog-
nition relevant to dementia (see below). Also, chronic studies
are warranted to assess if repeated administration affects the
separation factor between doses that elicit “antipsychotic”
effects and those that alter cognitive capacities.
Secondly, the novel antipsychotic lurasidone also impaired
PA performance (MED 10 mg/kp, i.p.). This is notable be-
cause lurasidone has been claimed to exhibit a favorable
cognitive profile in tests of passive avoidance, the radial arm
maze, and the Morris water maze, without impairing basal PA
performance (Enomoto et al. 2008; Ishiyama et al. 2007). In
addition, lurasidone has been reported to attenuate MK-801-
induced cognitive deficits at low doses (1–3 mg/kg p.o.)
(Ishiyama et al. 2007), suggesting that it may exhibit dose
separation between some of its pro-cognitive and
antipsychotic-like properties. It will therefore be interesting
to determine the extent to which lurasidone is of utility in
dementia patients.
Thirdly, the striking absence of memory impairment by
aripiprazole is consistent with its generally benign tolerance
profile. The partial agonist properties of aripiprazole at D2 and
5-HT1A receptors are claimed to provide “stabilizing” influ-
ence on neurotransmission, and this may underlie the drug’s
absence of interference on PA performance (Tamminga and
Carlsson 2002). Nevertheless, the incomplete blockade of D2
receptors by aripiprazole (due to its partial agonist activity at
these sites) may also render it less incisive for control of
psychotic symptoms or agitated states, as reflected in its
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Fig. 3 Effects of scopolamine and antipsychotics on step-through laten-
cy. Animals received antipsychotic drugs, 1 h before training session.
Each symbol represents mean±SEM latency to enter the dark compart-
ment (n=7–8). Squares indicate latency in training session, circles
indicate latency in test sessions. *p<0.05, **p<0.01, compared with
vehicle-injected control group using Mann–Whitney U test, following
significant Kruskal–Wallis ANOVA
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somewhat lesser capacity to reverse MK-801-induced hyper-
activity, as noted above, and its lack of clinical antipsychotic
efficacy in a trial of Alzheimer disease patients (De Deyn et al.
2005).
Fourthly, the present study examined the effects of antipsy-
chotics on the PA test in normal rats that were drug-naïve and
normally express a high level of performance. Therefore, the
present conditions detect impairments of memory performance
rather than cognitive enhancement (Marston et al. 2009). Ide-
ally, drugs would be active in MK-801-induced hyperactivity
tests while reducing immobility in the FST and being free of
interference on (or even improving) PA performance. Such a
screening battery could, theoretically, identify promising com-
pounds for subsequent characterization in more advanced tests
of anxio-depressive states and cognition. For example, drugs
could then be tested for their capacity to reverse memory
deficits elicited by muscarinic receptor antagonists such as
scopolamine (Gravius et al. 2011) and/or examine their effects
in aged animals that suffer from impairment arising from de-
cline in cerebral function or in mice that have been genetically
modified to alter beta-amyloid expression and neurologically
mimic Alzheimer’s disease (Lithner et al. 2011).
Mechanistic aspects
All of the drugs examined herein share the common property of
interacting with dopamine D2 receptors, the primary action
responsible for their antipsychotic-like profiles. In contrast,
the drugs exhibit markedly diverse profiles of action at seroto-
nergic receptor subtypes. In particular, the interaction of some
atypical antipsychotics with 5-HT1A, 5-HT6, and 5-HT7 re-
ceptors is likely to underlie their effects on antidepressant-like
behavior and cognitive performance (Arnt et al. 2008). Thus, 5-
HT1A receptor activation mediates the capacity of aripiprazole
to reverse social interaction deficits elicited by PCP (Newman-
Tancredi and Kleven 2011) and may also underlie some of
clozapine’s and lurasidone’s activity (Horiguchi and Meltzer
2012; Ishibashi et al. 2010). Lurasidone also has pronounced 5-
HT7 interaction, a property which has been claimed to contrib-
ute to its attenuation of PCP-induced novel object recognition
deficits (Horiguchi et al. 2011; Ishibashi et al. 2010).
Lastly, 5-HT6 antagonism is a prominent feature of the
receptor profile of clozapine and has been suggested to mediate
some of its “atypical” properties (Glatt et al. 1995). Indeed, 5-
HT6 receptor antagonists are active in models of cognition
relevant to psychotic disorders (Arnt and Olsen 2011; Rodefer
et al. 2008) as well as in tests of antidepressant-like and anxi-
olytic activity (Carr et al. 2011). 5-HT6 receptor antagonism
may also be a promising target for therapy of Alzheimer’s
disease (Gravius et al. 2011): A selective 5-HT6 antagonist,
LuAE58054, improved cognitive performance of Alzheimer
disease patients (H. Lundbeck A/S 2012). At a drug discovery
level, the novel compound, ADN-1184, possesses a promising
profile in rat models (active in the MK-801 and FST tests
without catalepsy or impairment of PA) and is characterized
by potent antagonism of 5-HT6 and 5-HT7 receptors, suggest-
ing that they mediate some of its therapeutic-like properties
(Kołaczkowski et al. 2013).
Conclusions and perspectives
To summarize, all the antipsychotics possess sub-optimal
profiles, mostly by eliciting memory-impairment or sedation
at antipsychotic-like range of doses—side effects that may be
of particular concern for elderly dementia patients with
preexisting cognitive deficits and motor difficulties. Improved
management of BPSD may be achieved by use of drugs that
incisively oppose glutamate-related psychosis but do not elicit
cognitive deficits or motor impairment. If such drugs also
possessed accentuated antidepressant properties, they could
constitute promising therapeutics for treatment of dementia-
related disturbances in elderly patients. While further investi-
gation would be desirable to determine the effects of drugs
under other treatment conditions (e.g., following repeated
administration or in conjunction with antidepressants), the
present comparative study provides a reference dataset by
which future drugs candidates can be evaluated at an early
stage of in vivo testing.
Concerning longer-term perspectives, the regulatory
framework for development of new BPSD drugs requires
clarification. Indeed, this should be addressed in a multidisci-
plinary context involving experts from pharmaceutical, med-
ical, and social sciences. A critical point is balancing somatic
risks induced by use of antipsychotics and their potential to
improve clinical status and quality of life of dementia patients
and caregivers. Recently, pimavanserin, a drug targeting psy-
chosis in Parkinson’s disease patients, was granted an expe-
dited path to NDA filing, suggesting that the regulatory envi-
ronment concerning psychotropic drugs for the elderly may be
changing. If so, there may be a rise in much-needed drug
discovery and development of novel treatments, offering hope
for the patients and families of those suffering from disorders
(such as BPSD) that are associated with dementia.
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